Skip to content
  • Members
  • Providers
  • Careers
  • Contact Us
  • Who We Are
  • Our Work Philosophy
  • Clinical Philosophy
  • Technological Advantage
  • Industry Solutions
  • OneArk
    Suite
  • Medicare
    Part D
  • Case Studies
  • Blog
  • Home
  • Who We Are
  • Our Work Philosophy
  • Clinical Philosophy
  • Technological Advantage
  • OneArk
    Suite
  • Industry Solutions
  • Medicare Part D
  • Case Studies
  • Blog
  • Contact Us
  • Members
  • Providers

For Providers

Recent Communications Resources

Communication to Pharmacies: General

  • COM-2023-001 Summary of Puerto Rico Administrative Order 556
  • ACT 142-2020 Emergency Provisional Fill Program coverage during the pre-approval process
  • FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
    May 2022
  • COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión español
  • COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión inglés
  • COM-2021 – 59 Operational Guide for the submission of the transaction COVID -19 – Oral antiviral drugs emergency use
  • Comunicado a Farmacias Ley -142-2020
  • COM-2021-053- LEY NUM. 35 2021
  • FDA Expands EUAs of Moderna’s and J&J’s COVID-19 Vaccines
    November 2021
  • FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age
    November 2021
  • Prior-authorization for Ivermectin due to Increased Use during COVID-19
    September 2021
  • Comunicado– Carta Normativa-2021-301-D
    April 2021
  • COVID-19 Vaccine administration requirements
    January 2021
  • Billing of Insulins Pens
    November 2020
  • Educational bulletin of the Pharmacy Audit process
    November 2020
  • Final Rule Modification of the Requirements for the Use of HIPAA National Council for Prescription Drug Programs (NCPDP) D.0 Standard
    October 2020
  • Orden Administrativa Núm. 441 del Departamento de Salud de Puerto Rico
    April 2020
  • Prior-authorization for hydroxychloroquine and chloroquine follow up after FDA’s drug safety communication
    April 2020
  • Carta de Clarificación- Medicamento Clopidogrel
    April 2020
  • Orden Administrativa Núm. 435 del Departamento de Salud de Puerto Rico
    April 2020
  • Recomendaciones de dispensación
    April 2020
  • Prior-authorization for hydroxychloroquine and chloroquine
    April 2020
  • Guía operacional sobre el despacho de medicamentos durante el estado de emergencia debido al COVID-19
    Marzo 2020
  • Entrega de medicamentos durante el estado de emergencia debido al COVID-19 y la Ley Núm. 19-2020
    Marzo 2020
  • Despacho de Medicamentos en Situaciones de Emergencia y/o durante Estado de Emergencia – Poveedores Puerto Rico
    Marzo 2020
  • Comunicado para proveedores sobre Emergencia COVID-19
    Marzo 2020
  • RE: Carta Normativa ASES 19-0305. Política pública de anti-discrimen a beneficiarios por razón de identidad de género, expresión de género u orientación sexual real o percibida, al solicitar o recibir servicios de salud.
    Marzo 2019
  • RE: ASES Normative Letter 19-0305. Public policy for non-discrimination to beneficiaries by reason of gender identity, expression of gender or real or perceived sexual orientation, when requesting or receiving health services.
    March 2019
  • Guía Básica a Proveedores para manejo sensible y adecuado al brindar servicios de salud a beneficiarios LGBTT+
    March 2019
  • Importance of the credentialization of pharmacies – Puerto Rico
    February 2019

Communication to Pharmacies: Safety

  • FDA Investigating Risk of Severe Hypocalcemia with Prolia
    November 2022
  • FDA Warns About Possible Increased Risk of Death with Copiktra
    July 2022
  • FDA Requires Revisions to Warnings for JAK Inhibitors
    June 2022
  • FDA Investigating Possible Increased Risk of Death with Ukoniq
    March 2022
  • Buprenorphine Medicines and the Risk of Dental Problems
    January 2022
  • FDA Requires Revisions to Warnings for JAK Inhibitors
    September 2021
  • Lamictal Drug Safety Communication
    May 2021
  • FDA Warns that Abuse and Misuse of Propylhexedrine Causes Serious Harm
    March 2021
  • Risk of serious heart-related problems and cancer with Xeljanz Xeljanz XR
    February 2021

Communication to Pharmacies: Education

  • First Disease-Modifying Therapy in Type 1 Diabetes
    December 2022
  • Ovarian Cancer Indications Withdrawn for PARP Inhibitors
    November 2022
  • Biosimilars and Interchangeability
    October 2022
  • Monkeypox and CDC Recommendations
    September 2022
  • FDA Authorizes Boosters for Moderna and Pfizer Bivalent Vaccine
    September 2022
  • FDA Authorizes Novavax COVID-19 Vaccine in Adolescents
    August 2022
  • FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine
    July 2022
  • FDA Amends Moderna and Pfizer-BioNTech COVID-19 Vaccine’s EUAs to Include Children 6 Months of Age and Older
    June 2022
  • Update on Heart Failure Guidelines – A Summary
    May 2022
  • New Indications and First-time Generics Approved by FDA from January 2022 to March 2022
    April 2022
  • FDA and CDC Recommend Second Booster to Certain Individuals
    March 2022
  • Summary of Emergency Use Authorizations for COVID-19 Treatment
    March 2022
  • FDA Grants Full Approval to Moderna’s COVID-19 Vaccine
    February 2022
  • FDA Issues Back-to-Back EUAs for Oral Treatments for COVID-19
    December 2021
  • FDA Expands EUAs of Pfizer-BioNTech and Moderna COVID-19 Vaccines
    November 2021
  • Increased Use of Ivermectin for the Prevention and Treatment of COVID-19
    September 2021
  • FDA Approves First Covid-19 Vaccine
    August 2021
  • EUA Amendment for COVID-19 Vaccine in Immunocompromised Individuals
    August 2021
  • New indications and first-time generics approved by the FDA from January 2021 to March 2021
    July 2021
  • Emergency use authorization for Sotrovimab for COVID-19
    June 2021
  • Pharmacists and vaccines
    May 2021
  • Emergency Use Authorization for COVID-19 Vaccine in Adolescents
    May 2021
  • FDA and CDC Lift Pause on Johnson Johnson (Janssen) COVID-19 Vaccine Use
    April 2021
  • Update to ACC Guidelines for Heart Failure Treatment
    April 2021
  • J&J- Janssen COVID-19 Vaccine Pause in the Use
    April 2021
  • NCCN Guidance COVID-19 Vaccination in Cancer Patients
    March 2021
  • Emergency use authorization for third COVID-19 vaccine
    March 2o21
  • New indications and first-time generics approved by the FDA from October 2020 to December 2020
    February 2021
  • FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
    January 2021

PharmNotes

  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021

Recalls

  • Drug Recall: Tirosint-Sol Oral Solution_IBSA Pharma Inc_022023
    February 2023
  • Drug Recall : Quinapril 20mg and 40mg Tablets_Lupin Pharmaceuticals_122022
    December 2022
  • Drug Recall : Daptomycin 500mg and 350mg Injection_122022
    December 2022
  • Drug Recall : Sodium Bicarbonate Injection 50mEq-50mL_Exela_112022
    November 2022
  • Drug Recall : Octreotide Acetate Injection_Mylan Institutional LLC_102022
    October 2022
  • Drug Recall : Quinapril and Hydrochlorothiazide 20mg-12.5mg_Aurobindo Pharma USA_102022
    October 2022
  • Drug Recall: Sodium Bicarbonate Injection Exela Pharma
    October 2022
  • Drug Recall:  Clopidogrel 75mg and Atenolol 25mg_GSMS Inc_092022
    September 2022
  • Drug Recall: Acyclovir Sodium Injection_Eugia US LLC_092022
    September 2022
  • Drug Recall: Insulin glargine-yfgn U-100 3mL Prefilled Pens_Mylan Pharmaceuticals Inc.
    July 2022
  • Drug Recall: Morphine Sulfate ER 30mg and 60m Tablets_Bryant Ranch Prepack Inc.
    June 2022
  • Drug Recall: Accupril 10mg, 20mg and 40mg Tablets_Pfizer
    April 2022
  • Drug Recall: Insulin Glargine 100units/mL_Mylan Pharmaceuticals Inc., a Viatris Company
    April 2022
  • Drug Recall: Symjepi 0.15mg and 0.3mg_Adamis Pharmaceuticals Corp.
    March 2022
  • Drug Recall: Orphenadrine 100mg ER tablets_Sandoz Inc.
    March 2022
  • Drug Recall: Accuretic and Quinapril-Hydrochlorothiazide_Pfizer
    March 2022
  • Drug Recall – Metformin ER Tablets 750mg – Viona Pharmaceuticals
    December 2021
  • Drug Recall – Nitroglycerin Lingual Spray 12g – Padagis
    December 2021
  • Drug Recall – Irbesartan and Irbesartan-Hydrochlorothiazide_Lupin Pharmaceuticals
    October 2021
  • Drug Recall – Methocarbamol 500mg tablets_Bryant Ranch Prepack
    October 2021
  • Drug Recall: Firvanq 50mg/ml – Azurity Pharmaceuticals, Inc. 
    September 2021
  • Drug Recall: Ruzurgi 10mg – Jacobus Pharmaceuticals Company, Inc.
    September 2021
  • Drug Recall: Chantix – Pfizer
    July 2021
  • Drug Recall: Metformin ER 750mg – Viona Pharmaceuticals Inc
    June 2021
  • Drug Recall with the Name: Drug Recall: NP Thyroid – Acella Pharmaceuticals LLC
    May 2021
  • Drug Recall: Guanfacine ER 2mg- – Apotex Corp.
    April 2021
  • Recall: Telmisartan 20mg – Alembic Pharmaceuticals, Inc.
    March 2021
  • Drug Recall: Spironolactone – Bryant Ranch Prepack.
    March 2021
  • Drug Recall: Adam’s Secret Extra Strength – Adamssecret.co
    February 2021
  • Recall: Enoxaparin Sodium Injection, USP – Apotex Corp.
    February 2021
  • Drug Recall with the name: Ketorolac 30 mg/mL Injection – Fresenius Kabi
    January 2021
  • Drug Recall (expansion): Metformin ER 750mg – Nostrum Lab
    January 2021
  • Drug Recall with the name: Drug Recall (extension): Paroex Chlorhexidine Gluconate Oral 15mL unit dose
    January 2021

Join Our Network

  • PharmPix Pharmacy Network Request Application
  • Exception Request Form
  • Important Information About Your Appeal Rights
  • Concurrent Utilization Review  
  • Pharmacy Rights and Responsibilities
  • Members Rights and Responsibilities
  • Pharmacy and Therapeutics Committee
  • Pricing Research Request Form
  • Prior Authorization Form
  • Retrospective Drug Utilization Review Program
  • Universal Claim Form
  • Pharmacy Credentialing/ Recredentialing
  • PharmPix Pharmacy Network Provider Fraud Waste and Abuse (FWA) and General Compliance Training
  • 2022 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
  • 2023 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
  • Fraud, Waste and/or Abuse Complaint Form
  • PharmPix Contact Information
  • Provider Complaint Form
  • Pharmacy Contracting
  • Pharmacy Credentialing Form
  • PharmPix Provider Manual

Get the details Watch Video

Ready for the demo? Contact us!

Navigation

  • Home
  • Who We Are
  • Our Work Philosophy
  • Clinical Philosophy
  • Technological Advantage
  • OneArk
    Suite
  • Industry Solutions
  • Medicare Part D
  • Case Studies
  • Blog
  • Contact Us
  • Members
  • Providers

Contact Us

  • 214.271.8100
    404.566.2000
    787.522.5252
  • 866.912.2804
  • info@pharmpix.com
  • TEXAS
    1400 Corporate Drive, Suite 225
    Irving, TX 75038
    GEORGIA
    One Alliance Center
    3340 Peachtree Road Suite 1800 Atlanta, GA 30326
    PUERTO RICO
    Metro Office Park
    Building 2, Suite 500
    Guaynabo, PR 00968

  • Terms and Conditions
  • Privacy Policy
Copyright © 2023 PharmPix Corporation. All Rights Reserved.